Digitizing Chef Intuition in Cell Therapy

Geoffrey Stephens, PhD, MBA
  • 0.0 (0)
  • Life Sciences
  • Updated Biweekly

AiCella, Inc., led by CEO Geoffrey Stephens, is leveraging artificial intelligence to transform the complex field of cell and gene therapy manufacturing. By utilizing their proprietary Insights platform, the company aims to resolve production bottlenecks and lower the high costs currently associated with these life-saving treatments. The technical framework incorporates a variety of machine learning algorithms and deep learning models to predict manufacturing outcomes and improve the quality of products like CAR-T and iPSC cells.

Episodes

  1. 2d ago

    AI-Driven Nondestructive Assessment of iPSC Pluripotency and Manufacturing Outputs

    Here, we explore the integration of artificial intelligence and machine learning into the complex field of cell and gene therapy manufacturing. We highlight the Insights™ platform, which harmonizes diverse data streams to create predictive models that enhance production efficiency and product quality, and demonstrate how deep learning can non-destructively evaluate stem cell pluripotency using early-stage microscopy and process data.

    21 min

  2. 2d ago

    Stopping AI Hallucinations in CGT Manufacturing

    The AiCella Insights platform introduces a manufacturing-aware RAG framework designed to unify fragmented data within the cell and gene therapy (CGT) sector. This specialized AI system addresses the limitations of generic large language models by grounding its responses in proprietary internal records, ensuring both factual accuracy and full audibility. The process involves standardizing multi-modal data, such as handwritten logs and electronic files, into a secure and searchable knowledge base.

    22 min

  3. 2d ago

    Overcoming the "Chefs Cooking Soup" Mentality

    Through case studies involving predictive modeling and automated image assessment, the sources demonstrate how data-driven workflows can identify critical production factors. Ultimately, this AI-driven approach seeks to accelerate decision-making and optimize biological processes to significantly enhance patient outcomes.

    21 min
  • 3 Episodes

About

AiCella, Inc., led by CEO Geoffrey Stephens, is leveraging artificial intelligence to transform the complex field of cell and gene therapy manufacturing. By utilizing their proprietary Insights platform, the company aims to resolve production bottlenecks and lower the high costs currently associated with these life-saving treatments. The technical framework incorporates a variety of machine learning algorithms and deep learning models to predict manufacturing outcomes and improve the quality of products like CAR-T and iPSC cells.

Information